Navigation Links
Nutra Pharma Announces Publication of Research on Treatment for,Multiple Sclerosis

BOCA RATON, Fla.--(BUSINESS WIRE)--Mar 22, 2007 - Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, has received notification of acceptance of its paper for publication in the Critical Reviews in Immunology special conference issue.

The article, entitled "Alpha-Cobratoxin as a possible therapy for Multiple Sclerosis; a review of the literature leading to its development for this application," discusses the background and reasoning behind ReceptoPharm's research on its treatment for Multiple Sclerosis (MS). The Company has completed Phase I studies and is preparing to begin its Phase II human clinical trials.

"We are honored to have our paper accepted for publication in such a well respected journal," commented Paul Reid, CEO of ReceptoPharm, Inc. "Alpha-Cobratoxin could play an important role in treating Multiple Sclerosis and we believe it is important to disseminate our research throughout the scientific community," he added.

Recently, ReceptoPharm announced it received a letter of intent to create a joint venture in China aimed at developing the Company's antiviral drug, RPI-MN, for the Chinese market. RPI-MN is ReceptoPharm's lead drug candidate being researched for the treatment of HIV/AIDS and other viral disorders.

About Critical Reviews in Immunology

The great advances in immunology in recent years make this field one of the most rapidly growing in biological sciences. Critical Reviews(TM) in Immunology presents a balanced overview of contemporary immunology and melds together molecular immunology and immunobiology. The Journal is published six times each year.

http://www.begellhouse.com/journals/2ff21abf44b19838.html

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, l icensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.ReceptoPharm.com

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The publication of the ReceptoPharm article should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact

Nutra Pharma Corp.
Investor Relations:
David Isserman, 877-895-5647
IR@nutrapharma.com


'"/>




Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  Echo Therapeutics, Inc. ... company focused on non-invasive continuous glucose monitoring ... announced that it will host a webcast ... 2015 at 9:00 a.m. Eastern Time to ... corporate strategy, advancements in its CGM system, ...
(Date:2/8/2016)... historic vote among its members this weekend, the Shinnecock Indian Nation voted ... dispensary on tribal land near Southampton . ... patients in the state,s Medical Cannabis Program. --> ... the state,s Medical Cannabis Program. --> Tribal members voted ... from the State of New York as a ...
(Date:2/8/2016)... Switzerland and PALO ALTO, Calif. , Feb. ... and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical ... of retinal disease, announced today agreements for the clinical ... will manufacture material at multiple sites, including Slough (UK), ... --> --> Retinal diseases, such as ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... ... will ensure lab personnel have a basic understanding of the techniques they use ... Enhanced understanding will help them reduce waste and rework to create a leaner ...
(Date:2/9/2016)... ... February 09, 2016 , ... Sir Grout, the leading ... proud to announce that many of their franchises have received the Super Service ... surface restoration franchises received customer recognition through positive reviews and testimonials, as well ...
(Date:2/8/2016)... ... , ... CURE Media Group , the nation’s leading digital and print ... Awards event , which will annually honor individuals making heroic contributions in the field ... MM Heroes Awards nomination process is officially open through February 17 for patients, ...
(Date:2/8/2016)... ... February 08, 2016 , ... Stephanie Hebert ... the beginning of a new charity campaign. As part of their ongoing community ... (CASA). In the belief that children deserve a voice, and in the spirit ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that ... you are not alone. According to the Center for Disease Control and Prevention (CDC), ... 2 diabetes and certain types of cancer, some of the leading causes of preventable ...
Breaking Medicine News(10 mins):